Drugs / NKT3447
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06264921 | Feb 2024 → Apr 2025 | endometrial carcinoma, gastric carcinoma, metastatic neoplasm, ovarian carcinoma +3 | NiKang Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKT3447 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06264921 ↗ |
| Action | Inhibit | “Oral CDK2 inhibitor” NCT06264921 ↗ |
| Route | Oral | “oral dosing NKT3447” NCT06264921 ↗ |
| Target | CDK2 | “Oral CDK2 inhibitor” NCT06264921 ↗ |